Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Tisdale, John F  [Clear All Filters]
2024
Demirci S, Khan MBN, Hinojosa G, Le A, Leonard A, Essawi K, Gudmundsdottir B, Liu X, Zeng J, Inam Z, et al. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models. Cytotherapy. 2024.
2023
Everette KA, Newby GA, Levine RM, Mayberry K, Jang Y, Mayuranathan T, Nimmagadda N, Dempsey E, Li Y, Bhoopalan SVelan, et al. Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice. Nat Biomed Eng. 2023.
Inam Z, Tisdale JF, Leonard A. Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease. Expert Rev Hematol. 2023.
Mayuranathan T, Newby GA, Feng R, Yao Y, Mayberry KD, Lazzarotto CR, Li Y, Levine RM, Nimmagadda N, Dempsey E, et al. Potent and uniform fetal hemoglobin induction via base editing. Nat Genet. 2023.
Tamaoki N, Siebert S, Maeda T, Ha N-H, Good ML, Huang Y, Vodnala SK, Haro-Mora JJ, Uchida N, Tisdale JF, et al. Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells. Cell Rep Methods. 2023;3(4):100460.
2022
Shin T-H, Zhou Y, Chen S, Cordes S, Grice MZ, Fan X, Lee B-C, AlJanahi AA, Hong SGun, Vaughan KL, et al. Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions. Blood. 2022.
2021
Leonard A, Sharma A, Uchida N, Stroncek D, Panch SR, West K, Molloy E, Hughes TE, Hauffe S, Taylor T, et al. Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Adv. 2021;5(9):2403-2411.
Abraham AA, Tisdale JF. Gene Therapy for Sickle Cell Disease - Moving from the Bench to the Bedside. Blood. 2021.
Drysdale CM, Nassehi T, Gamer J, Yapundich M, Tisdale JF, Uchida N. Hematopoietic-Stem-Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies. Cell Stem Cell. 2021;28(2):191-208.
Alzahrani M, Damlaj M, Jeffries N, Alahmari B, Singh A, Rondelli D, Tisdale JF, Saraf SL, Hsieh MM. Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. Br J Haematol. 2021.
2020
Demirci S, Zeng J, Wu Y, Uchida N, Shen AH, Pellin D, Gamer J, Yapundich M, Drysdale C, Bonanno J, et al. BCL11A enhancer edited hematopoietic stem cells persist in rhesus monkeys without toxicity. J Clin Invest. 2020.
Haro-Mora JJ, Uchida N, Demirci S, Wang Q, Zou J, Tisdale JF. Biallelic correction of sickle cell disease-derived iPSCs confirmed at the protein level through serum-free iPS-sac/erythroid differentiation. Stem Cells Transl Med. 2020.
2019
M Murad H, Liem RI, Lang ES, Akl EA, Meerpohl JJ, DeBaun MR, Tisdale JF, Brandow AM, Lanzkron SM, Chou ST, et al. 2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood Adv. 2019;3(23):3945-3950.
Demirci S, Leonard A, Haro-Mora JJ, Uchida N, Tisdale JF. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges. Adv Exp Med Biol. 2019.
Demirci S, Mora JJHaro, Yapundich M, Drysdale C, Gamer J, Nassehi T, Bonifacino AC, Krouse AE, Linde NS, Donahue RE, et al. Fetal hemoglobin (HbF) and F-cell variance in mobilized CD34 cell transplanted rhesus monkeys. Exp Hematol. 2019.
Métais J-Y, Doerfler PA, Mayuranathan T, Bauer DE, Fowler SC, Hsieh MM, Katta V, Keriwala S, Lazzarotto CR, Luk K, et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 2019;3(21):3379-3392.
Ruiz JPablo, Chen G, Mora JJesus Haro, Keyvanfar K, Liu C, Zou J, Beers J, Bloomer H, Qanash H, Uchida N, et al. Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system. Stem Cell Res. 2019;41:101600.
2018
Melendez-Munoz R, Marchalik R, Jerussi T, Dimitrova D, Nussenblatt V, Beri A, Rai K, Wilder JS, A Barrett J, Battiwalla M, et al. Cytomegalovirus infection incidence and risk factors across diverse hematopoietic cell transplantation platforms using a standardized monitoring and treatment approach: a comprehensive evaluation from a single institution. Biol Blood Marrow Transplant. 2018.
2016
Uchida N, R Weitzel P, Shvygin A, Skala LP, Raines L, Bonifacino AC, Krouse AE, Metzger ME, Donahue RE, Tisdale JF. Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model. Mol Ther Methods Clin Dev. 2016;3:16059.
2014
Uchida N, Hsieh MM, Platner C, Saunthararajah Y, Tisdale JF. Decitabine Suspends Human CD34+ Cell Differentiation and Proliferation during Lentiviral Transduction. PLoS One. 2014;9(8):e104022.
Hsieh MM, Fitzhugh CD, R Weitzel P, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF. Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype. JAMA. 2014;312(1):48-56.